ClinicalTrials.gg
CompletedNCT01867164Updated Dec 24, 2013Results posted

A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis

A Phase 3 interventional study of Gynoclin V and Vagitrol V in Vaginitis and Infectious Vaginosis, sponsored by Janssen-Cilag, S.A.. Completed at 2 sites in Mexico. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-24.

Sponsored by Janssen-Cilag, S.A. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis (polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli).

Read the detailed description

This is a prospective (study following participants forward in time), open-label (all people know the identity of the intervention), randomized (the study drug is assigned by chance), comparative, parallel (a clinical trial comparing the response in 2 or more groups of participants receiving different treatments) double-arm, multi-center (when more than 1 hospital or medical school team work on a medical research study) study. The study consists of 3 phases: Screening phase on Visit 1 (Day -3/1); Inclusion or treatment phase on Visit 2 (Day 1); and Treatment or monitoring phase (3 days after treatment) on Visit 3 (Day 7 for Gynoclin V and Day 13 for Vagitrol V) and Visit 4 (Day 12 for Gynoclin V and Day 18 for Vagitrol V). Participants will be randomly assigned to 1 of the 2 treatment groups: Gynoclin V and Vagitrol V. Participants in Gynoclin V group will be administered 1 ovule (containing 80 milligram [mg] terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide) vaginally every 24 hours at night, for 3 days. Participants in the Vagitrol V group will be administered 1 ovule (containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin) vaginally every 24 hours at night, for 10 days. Primarily, participants will be evaluated for signs and symptoms, characteristics of vaginal discharge, changes in vulvar region, changes in cervix and presence of bacteria, fungi and/or parasites. Participants' safety will be monitored throughout the study.

02

Conditions studied

  • Vaginitis
  • Infectious Vaginosis

Browse trials for

Keywords

  • Vaginitis
  • Infectious vaginosis
  • Terconazole
  • Clindamycin
  • Fluocinolone
  • Metronidazole
  • Nystatin
03

In context

Vaginitis

98 studies on the registry are indexed under Vaginitis; 12 are open to participants now.

This study's enrollment of 160 is above the median of 108 across 71 interventional studies indexed under Vaginitis.

Browse Vaginitis studies →

Lead sponsor

Janssen-Cilag, S.A. is the lead sponsor of 21 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants presenting clinical symptoms compatible with vaginitis/bacterial vaginosis, with any of the following symptoms being the reason for the consultation: pruritus (itchiness), vulvar burning, as well as presenting leukorrhea (a clear or white discharge from the vagina, consisting mainly of mucus) as an accompanying symptom
  • Participant who agrees to return at the 7th and 13th day after starting the treatment
  • Participant who agrees to abstain from sexual relations for the 13 days of the study
  • Participant who have signed to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Participant with a known allergy to vaginal treatments
  • Participants who have received treatment for the current condition in the 10 days before the date of inclusion, or is currently receiving antibiotics (drug used to stop or slow down the growth of germs), antifungals, anti-parasitics or systemic
  • Participant with suspected pregnancy or currently breastfeeding
  • Participant who has received unknown drugs or experimental drugs within the 3 months before inclusion
  • Participant known to be a carrier of a severe (very serious, life threatening) disease that alters the metabolism or excretion of the drugs used (liver or kidney disease)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Gynoclin V

    One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.

    Drug: Gynoclin V

  • Experimental
    Vagitrol V

    One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.

    Drug: Vagitrol V

Interventions

  • DrugGynoclin V

    One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.

  • DrugVagitrol V

    One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment

    Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.

    Time frame: 3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)

  2. Percentage of Participants With Presence or Absence of Symptoms 8 Days After Treatment

    Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.

    Time frame: 8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)

  3. Percentage of Participants With the Presence of Microorganisms (Single-celled, Tiny Organisms That Include Fungi, Bacteria, Viruses) 3 Days After Treatment

    Percentage of participants with the presence of microorganisms (Candida albicans, Candida species, Gardnerella vaginalis, Vaginal flora, Lactobacillus species) in the wet mount, KOH, gram stain and vaginal discharge culture (candida and symptomatology) 3 days after treatment.

    Time frame: 3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)

Secondary outcomes

  1. Percentage of Participants With Response to Treatment Assessed by Participant

    Response to treatment was evaluated by participant using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).

    Time frame: 8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)

  2. Percentage of Participants With Response to Treatment Assessed by Physician

    Response to treatment was evaluated by Physician using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).

    Time frame: 8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)

07

Results

Posted Dec 24, 2013

Participant flow

Participant flow — Overall Study
MilestoneGynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)
Started8179
Completed8179
Not completed00

Outcome measures

PrimaryPercentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment

Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.

Time frame:
3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment
Percentage of ParticipantsGynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)
Itching: Absent67.179.2
Itching: Present32.920.8
Burning: Absent78.588.3
Burning: Present21.511.7
Sudden vulvar pain: Absent95.090.9
Sudden vulvar pain: Present5.09.1
PrimaryPercentage of Participants With Presence or Absence of Symptoms 8 Days After Treatment

Participants were evaluated for presence or absence of symptoms (itching, burning and sudden vulvar pain) in response to treatment.

Time frame:
8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Presence or Absence of Symptoms 8 Days After Treatment
Percentage of ParticipantsGynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)
Itching: Absent88.385.3
Itching: Present11.714.7
Burning: Absent93.592
Burning: Present6.58
Sudden vulvar pain: Absent97.489.3
Sudden vulvar pain: Present2.610.7
PrimaryPercentage of Participants With the Presence of Microorganisms (Single-celled, Tiny Organisms That Include Fungi, Bacteria, Viruses) 3 Days After Treatment

Percentage of participants with the presence of microorganisms (Candida albicans, Candida species, Gardnerella vaginalis, Vaginal flora, Lactobacillus species) in the wet mount, KOH, gram stain and vaginal discharge culture (candida and symptomatology) 3 days after treatment.

Time frame:
3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)
Reported as:
Number · Percentage of Participants
Percentage of Participants With the Presence of Microorganisms (Single-celled, Tiny Organisms That Include Fungi, Bacteria, Viruses) 3 Days After Treatment
Percentage of ParticipantsGynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)
Candida albicans2.50
Candida species, Gardnerella vaginalis9.81.3
Vaginal Flora55.658.2
Lactobacillus species28.436.7
No culture performed3.73.8
SecondaryPercentage of Participants With Response to Treatment Assessed by Participant

Response to treatment was evaluated by participant using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).

Time frame:
8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Response to Treatment Assessed by Participant
Percentage of ParticipantsGynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)
Poor1.301.30
Moderate04.00
Good36.4029.40
Excellent62.3065.30
SecondaryPercentage of Participants With Response to Treatment Assessed by Physician

Response to treatment was evaluated by Physician using a 5-point numerical scale: 1=No response (no improvement or condition even worsened); 2=Poor (No symptoms disappeared and symptoms are moderate to severe) 3=Moderate (improvement and symptoms are of moderate intensity); 4=Good (much improvement, but there are still some occasional mild symptoms); 5=Excellent (all symptoms disappeared).

Time frame:
8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Response to Treatment Assessed by Physician
Percentage of ParticipantsGynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)
Poor1.301.30
Moderate05.30
Good28.6026.70
Excellent70.1066.70

Adverse events

Collected over Baseline up to Day 13 for Gynoclin V and Day 18 for Vagitrol V. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)—0/81 (0%)1/81 (1.2%)
Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)—0/79 (0%)1/79 (1.3%)
Most frequent other events
Most frequent other events
EventGynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)
Fungal InfectionsInfections and infestations0/811/79
HeadacheNervous system disorders1/810/79

Baseline characteristics

Participants who received at least 1 dose of study medication and who were evaluated for efficacy parameters were included in Intent-to-treat (ITT) population.

Age Continuous
Age Continuous(Years)Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)Total
Mean30.69 ± 7.1730.56 ± 7.5030.63 ± 7.33
Sex: Female, Male
Sex: Female, Male(Participants)Gynoclin V (Terconazole+Clindamycin+Fluocinolone Acetonide)Vagitrol V (Metronidazole+Fluocinolone Acetonide+Nystatin)Total
Female8179160
Male000
08

Study locations

2 sites
  • DF, Mexico
  • Mexico D.F., Mexico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2013
First posted
Jun 3, 2013
Start
Dec 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Dec 24, 2013
Last update
Dec 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01867164
Responsible party
Sponsor
First posted
Jun 3, 2013
Start date
Dec 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Dec 24, 2013
Last update
Dec 24, 2013

Study contacts

Janssen-Cilag S.A. Clinical Trial
study director · Janssen-Cilag, S.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion